To the editor

New England Journal of Medicine

Volumn 364, Issue 14, 2011, Pages 1374-

  Underhill, Kristen ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO;

CHEMOPROPHYLAXIS; COGNITIVE THERAPY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RECIPIENT; RISK REDUCTION; SEXUAL BEHAVIOR;

EID: 79953797784     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165-72.
2. Underhill K, Operario D, Skeer MR, Mimiaga MJ, Mayer KH. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010;55:8-13.
3. Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008;3(5):e2077.
4. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008;22:1829-39.
5. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54:548-55.